GRN and urinary bladder cancer: Our results provide the first demonstration that progranulin targeting may work as a novel therapeutic approach in bladder cancer extending previous results from breast carcinoma [36] and hepatocellular carcinoma-derived cell lines [37], where progranulin targeting by either antisense strategies [36] or inhibitory antibodies [37] respectively inhibits tumorigenicity.